摘要:
The present invention deals with heterotrimeric AMP-activated protein kinase (AMPK) comprising a fluorophore pair wherein the conformational change can be measured by FRET. It represents an advanced tool to screen and identify AMPK interactors in vitro and in cells in vivo. Such invention can also be considered as a reporter of the cellular energy status as it allows the spatiotemporal monitoring, in situ, of fluctuations in the ratio of AMP and ADP versus ATP.
摘要:
The invention provides an isolated multiple integration element (MIE) comprising, in the specified order: a) a homing endonuclease site (HE); b) a promoter selected from the group consisting of AOX1, FLD1, FMD1, GAP and TEF1; c) a BstBI restriction site; d) a sequence encoding a secretion signal; e) a Ncol restriction site; f) a selection marker gene; g) a Pmel restriction site; h) a DNA sequence encoding a detection and/or purification polypeptide; i) a terminator selected from the group consisting of AOX1, FLD1, FMD1, GAP and TEF1; and j) a BstXI restriction site, wherein the HE and BstXI sites are selected such that HE and BstXI result in compatible cohesive ends when cut by the homing endonuclease and the BstXI restriction enzyme, respectively, and the ligation product of HE and BstXI cohesive ends can neither be cleaved by the homing endonuclease nor the BstXI restriction enzyme.
摘要:
The present invention relates to an engineered polypeptide comprising at least one adenovirus fibre protein N-terminal fragment specifically binding to an adenovirus fibre protein binding cleft of a penton base protomer and (i) a non-adenoviral peptide and/or (ii) is covalently or non-covalently coupled to a drug or label. The invention further relates to a VLP comprising the engineered polypeptide(s) of the invention bound to adenovirus fibre protein binding cleft of adenovirus penton base protomers forming the VLP. Further subject matter of the invention are nucleic acids and vectors for cloning and expression of the engineered polypeptide. The invention also relates to methods for producing the engineered polypeptide and the VLP. The engineered polypeptide and the VLP are useful in the treatment or prevention of infectious diseases, immune diseases and cancer.
摘要:
The present invention is based on the discovery that large parts of the genome of nucleopolyhedtovirus (NPV)-alpha baculovirus clade Ia viruses can be deleted with out deleterious effect on the usability of the virus comprising such genome in the infection of cells in cell culture. Accordingly, the present invention provides NPY-alpha baculovirus clade Ia genome which is reduced in size in comparison to the respective native NPV-alpha baculovirus clade Ia genome, such genomes comprising heterologous nucleotides, viruses comprising either of these genomes, cells infected with such viruses and methods for producing such viruses and cells.
摘要:
The invention relates to a method of preparing engineered target polypeptides (TP) comprising in its amino acid sequence one or more, identical or different, non-canonical amino acid (ncAA) residues, by expressing said TP in an insect cell line (ICL) and by expressing novel orthogonal bacterial aminoacyl tRNA synthetase/tRNA pairs in said ICL; a baculoviral shuttle vector (bacmid) suitable or introducing the genetic information of said orthogonal tRNA synthetase/tRNA into said ILC; particular expression cassettes for expressing said particular tRNAs in said ILC; TPs obtained by said method; as we as a kit for preparing said TPs.